Validation of the Coronary Artery Calcium Data and Reporting System (CAC-DRS): Dual importance of CAC score and CAC distribution from the Coronary Artery Calcium (CAC) consortium.


Journal

Journal of cardiovascular computed tomography
ISSN: 1876-861X
Titre abrégé: J Cardiovasc Comput Tomogr
Pays: United States
ID NLM: 101308347

Informations de publication

Date de publication:
Historique:
received: 31 01 2019
revised: 12 03 2019
accepted: 25 03 2019
pubmed: 7 4 2019
medline: 7 7 2020
entrez: 7 4 2019
Statut: ppublish

Résumé

The Coronary Artery Calcium Data and Reporting System (CAC-DRS), which takes into account the Agatston score category (A) and the number of calcified vessels (N) has not yet been validated in terms of its prognostic significance. We included 54,678 patients from the CAC Consortium, a large retrospective clinical cohort of asymptomatic individuals free of baseline cardiovascular disease (CVD). CAC-DRS groups were derived from routine, cardiac-gated CAC scans. Cox proportional hazards regression models, adjusted for traditional CVD risk factors, were used to assess the association between CAC-DRS groups and CHD, CVD, and all-cause mortality. CAC-DRS was then compared to CAC score groups and regional CAC distribution using area under the curve (AUC) analysis. The study population had a mean age of 54.2 ± 10.7, 34.4% female, and mean ASCVD score 7.3% ± 9.0. Over a mean follow-up of 12 ± 4 years, a total of 2,469 deaths (including 398 CHD deaths and 762 CVD deaths) were recorded. There was a graded risk for CHD, CVD and all-cause mortality with increasing CAC-DRS groups ranging from an all-cause mortality rate of 1.2 per 1,000 person-years for A0 to 15.4 per 1,000 person-years for A3/N4. In multivariable-adjusted models, those with CAC-DRS A3/N4 had significantly higher risk for CHD mortality (HR 5.9 (95% CI 3.6-9.9), CVD mortality (HR4.0 (95% CI 2.8-5.7), and all-cause mortality a (HR 2.5 (95% CI 2.1-3.0) compared to CAC-DRS A0. CAC-DRS had higher AUC than CAC score groups (0.762 vs 0.754, P < 0.001) and CAC distribution (0.762 vs 0.748, P < 0.001). The CAC-DRS system, combining the Agatston score and the number of vessels with CAC provides better stratification of risk for CHD, CVD, and all-cause death than the Agatston score alone. These prognostic data strongly support new SCCT guidelines recommending the use CAC-DRS scoring.

Sections du résumé

BACKGROUND BACKGROUND
The Coronary Artery Calcium Data and Reporting System (CAC-DRS), which takes into account the Agatston score category (A) and the number of calcified vessels (N) has not yet been validated in terms of its prognostic significance.
METHODS METHODS
We included 54,678 patients from the CAC Consortium, a large retrospective clinical cohort of asymptomatic individuals free of baseline cardiovascular disease (CVD). CAC-DRS groups were derived from routine, cardiac-gated CAC scans. Cox proportional hazards regression models, adjusted for traditional CVD risk factors, were used to assess the association between CAC-DRS groups and CHD, CVD, and all-cause mortality. CAC-DRS was then compared to CAC score groups and regional CAC distribution using area under the curve (AUC) analysis.
RESULTS RESULTS
The study population had a mean age of 54.2 ± 10.7, 34.4% female, and mean ASCVD score 7.3% ± 9.0. Over a mean follow-up of 12 ± 4 years, a total of 2,469 deaths (including 398 CHD deaths and 762 CVD deaths) were recorded. There was a graded risk for CHD, CVD and all-cause mortality with increasing CAC-DRS groups ranging from an all-cause mortality rate of 1.2 per 1,000 person-years for A0 to 15.4 per 1,000 person-years for A3/N4. In multivariable-adjusted models, those with CAC-DRS A3/N4 had significantly higher risk for CHD mortality (HR 5.9 (95% CI 3.6-9.9), CVD mortality (HR4.0 (95% CI 2.8-5.7), and all-cause mortality a (HR 2.5 (95% CI 2.1-3.0) compared to CAC-DRS A0. CAC-DRS had higher AUC than CAC score groups (0.762 vs 0.754, P < 0.001) and CAC distribution (0.762 vs 0.748, P < 0.001).
CONCLUSION CONCLUSIONS
The CAC-DRS system, combining the Agatston score and the number of vessels with CAC provides better stratification of risk for CHD, CVD, and all-cause death than the Agatston score alone. These prognostic data strongly support new SCCT guidelines recommending the use CAC-DRS scoring.

Identifiants

pubmed: 30952612
pii: S1934-5925(19)30062-0
doi: 10.1016/j.jcct.2019.03.011
pmc: PMC6765460
mid: NIHMS1526186
pii:
doi:

Types de publication

Journal Article Multicenter Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-17

Subventions

Organisme : NHLBI NIH HHS
ID : L30 HL110027
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.

Références

Atherosclerosis. 2015 Jan;238(1):126-31
pubmed: 25479801
AJR Am J Roentgenol. 2005 Dec;185(6):1542-5
pubmed: 16304010
Radiology. 2015 Jul;276(1):82-90
pubmed: 25759972
JACC Cardiovasc Imaging. 2016 Dec;9(12):1407-1416
pubmed: 27085449
Atherosclerosis. 2014 Nov;237(1):1-4
pubmed: 25173946
JACC Cardiovasc Imaging. 2017 Aug;10(8):923-937
pubmed: 28797416
JACC Cardiovasc Imaging. 2014 May;7(5):476-486
pubmed: 24831208
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Eur Heart J. 2018 Nov 1;39(41):3727-3735
pubmed: 30212857
J Cardiovasc Comput Tomogr. 2018 May - Jun;12(3):185-191
pubmed: 29793848
JAMA. 2014 Apr 9;311(14):1406-15
pubmed: 24682252
Eur Heart J. 2012 May;33(10):1201-13
pubmed: 22547221
Am J Cardiol. 2009 Jan 1;103(1):59-63
pubmed: 19101230
J Cardiovasc Comput Tomogr. 2017 Mar - Apr;11(2):157-168
pubmed: 28283309
J Am Coll Cardiol. 2018 Jul 24;72(4):434-447
pubmed: 30025580
J Cardiovasc Comput Tomogr. 2017 Jan - Feb;11(1):54-61
pubmed: 27884729
J Thorac Imaging. 2017 Sep;32(5):W54-W66
pubmed: 28832417
Am J Cardiol. 2015 May 1;115(9):1229-34
pubmed: 25743208
J Am Heart Assoc. 2018 Oct 16;7(20):e010471
pubmed: 30371271
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209
pubmed: 30423391
Clin Cardiol. 2014 Aug;37(8):456-61
pubmed: 25138770

Auteurs

Omar Dzaye (O)

Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States; Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Radiology and Neuroradiology, Charité, Berlin, Germany.

Ramzi Dudum (R)

Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States; Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.

Mohammadhassan Mirbolouk (M)

Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States.

Olusola A Orimoloye (OA)

Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States.

Albert D Osei (AD)

Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States.

Zeina A Dardari (ZA)

Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States.

Daniel S Berman (DS)

Department of Nuclear Cardiology/Cardiac Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Michael D Miedema (MD)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, United States.

Leslee Shaw (L)

Department of Radiology and Medicine, Weill Cornell Medical College, New York, NY, United States.

Alan Rozanski (A)

Department of Medicine, St. Luke's Roosevelt Hospital Center, New York, NY, United States.

Matthias Holdhoff (M)

Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.

Khurram Nasir (K)

Department of Medicine, Yale School of Medicine, New Haven, CT, United States; Center for Outcomes Research & Evaluation, Yale School of Medicine, New Haven, CT, United States.

John A Rumberger (JA)

Department of Cardiovascular Imaging, Princeton Longevity Center, Princeton, NJ, United States.

Matthew J Budoff (MJ)

Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, United States.

Mouaz H Al-Mallah (MH)

Cardiovascular Imaging and PET, Houston Methodist DeBakey Heart & Vascular Center, Houston Texas, Texas, United States.

Ron Blankstein (R)

Cardiovascular Imaging Program, Brigham and Women's Hospital and Harvard Medical School, United States.

Michael J Blaha (MJ)

Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States; Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States. Electronic address: mblaha1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH